RARB and breast cancer: The ability of genistein to epigenetically modulate aberrant gene expression patterns in BC cells was confirmed by Lubecka et al. (2018) who showed that exposure of MCF-7 and MDA-MB-231 cells to the combination of genistein and clofarabine (2-chloro-2′-fluoro-2′-deoxyarabinosyladenine, ClF), a second-generation 2′-deoxyadenosine analog capable of regulating epigenetic processes, resulted in strong upregulation and activation of DNA-methylation-silenced tumor suppressors, including PTEN, retinoic acid receptor beta (RARB), and CDKN1A, and consequent activation of apoptosis [309].